Syndicate content

Archive - Jan 28, 2020

Date
  • All
  • Jan
  • Feb
  • Mar
  • Apr
  • May
  • Jun
  • Jul
  • Aug
  • Sep
  • Oct
  • Nov
  • Dec

Biological Dynamics Enters Collaboration with Microsoft to Advance Access to Novel Diagnostic Biomarker Solutions to Life Science Customers

On January 28, 2020, Biological Dynamics, Inc., an innovative diagnostic company committed to improving global health, announced it has been accepted to Microsoft's One Commercial Partner (OCP) program. The company will use the comprehensive development solutions available to OCP partners to develop and establish a research service delivery model, to provide Microsoft’s Life Science partners and customers access to cutting-edge molecular diagnostic solutions powered by Biological Dynamics’ novel isolation platform. Within the last decade, the discoveries brought forward by personalized medicine have transformed both basic research and drug development. Today, drug developers continue to expand their liquid biopsy toolsets beyond traditional techniques, incorporating the results of genetic and proteomic analysis of the content of the emerging class of biomarkers, such as extracellular vesicles (EVs). Today, the success of this biomarker-driven drug development model is powered by early integration of novel diagnostic methods with robust data and business platforms, such as Microsoft Azure and OCP, to help ensure seamless data sharing and compliance with major global security and privacy standards. Biological Dynamics is developing a suite of novel assays for pharmaceutical applications, with initial focus on detection of DNA and EV-associated biomarkers and liquid biopsy panels. The assays are being built upon Verita™, the company’s proprietary biomarker isolation platform that isolates DNA and extracellular vesicles (EVs) from plasma and serum without the need to pre-process samples.